CG Oncology, Inc. (CGON) stock
CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$84.78+10.38 (+13.95%)
Close on Nov 16, 2026Market cap $7.51BP/E –Yield –
CG Oncology operating margin
Operating margin is operating income as a percentage of revenue.
CG Oncology's operating margin for the twelve months ending Sep 30, 2026 was -4293.5%. For fiscal 2025 it was -4722.1%, against -10067.3% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -4722.1% | +5345.1 |
| FY2024 | Dec 31, 2024 | -10067.3% | +17113.6 |
| FY2023 | Dec 31, 2023 | -27180.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -3943.2% | −874.2 |
| Q2 FY2026 | Jun 30, 2026 | -7467.7% | +73693.9 |
| Q1 FY2026 | Mar 31, 2026 | -6130.1% | +2214.0 |
| Q4 FY2025 | Dec 31, 2025 | -2097.3% | +63705.0 |
| Q3 FY2025 | Sep 30, 2025 | -3069.0% | +20222.0 |
| Q1 FY2025 | Mar 31, 2025 | -81161.5% | −76914.1 |
| Q4 FY2024 | Dec 31, 2024 | -8344.1% | +1927155.9 |
| Q3 FY2024 | Sep 30, 2024 | -65802.3% | +90231.0 |
| Q2 FY2024 | Jun 30, 2024 | -23291.0% | −18280.2 |
| Q1 FY2024 | Mar 31, 2024 | -4247.4% | – |
| Q4 FY2023 | Dec 31, 2023 | -1935500.0% | – |
| Q3 FY2023 | Sep 30, 2023 | -156033.3% | – |
| Q1 FY2023 | Mar 31, 2023 | -5010.8% | – |
See a number that looks wrong?